INSULIN ASPART, ULTRARAPID 100 UI/ml, 3ml, pref. pen

NST DINJINSAU3AP-

Valid Article

Former Code(s): DINJINSH3APR2 DINJINSA3APU2 DINJINSAU3APN

The product is supplied (and stored) sterile, it must remain sterile until its use. Sterile = state of being free from all living microorganisms.
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
A018006 - Hypodermic needles pen injectors
European Medical Device Nomenclature (EMDN) is the nomenclature of use by manufacturers when registering their medical devices in the EUDAMED database. EMDN is characterised by its alphanumeric structure that is established in a seven-level hierarchical tree.
A10AB05
Anatomical Therapeutic Chemical Classification according to WHOCC
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.

OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

https://unicat.msf.org/web/image/product.template/588504/image_1920?unique=2f6ba5b

This combination does not exist.

Add article to list

   

Add Kit To Wishlist

   

INSULIN ULTRARAPID, pre-filled pen

Image

Full Name

Novo Rapid FlexPen® (Nordisk) or Insulin Aspart ImpactFlexPen® (Sanofi)

Therapeutic Action

Pancreatic hormone, hypoglycaemic

Rapid-acting (or short-acting) insulin analogue

Action profile:

  • onset of action: 15 - 30 mn
  • peak action: 1.5 - 3 hours
  • duration of action: 3 - 8 hours

These action profiles are based on subcutaneous injections and are approximate. They depend on the dose injected, the type and brand of insulin, and may vary significantly from one patient to another.

See Preliminary remarks on Insulins

Indications

Diabetes

Management of acute hyperglycaemia

Due to the faster onset of action, the ultra rapid insulin should be administered immediately before a meal to effectively cover post-meal glycaemic excursions.

Insulin pre-filled pens are the preferred option for the patient self-administration (and OPD use).

Instructions for use

A portable, hand-held device, typically in the form of a large pen, prefilled with a pharmaceutical agent and intended to be used by a patient to subcutaneously inject a dose of the pharmaceutical via a replaceable needle. The device typically includes a dial for dosing and is discarded when the pharmaceutical is exhausted and is therefore used over a short period (single-use).

Must be given as deep SC injection only.

Before using insulin for the first time, allow it to reach room temperature for 1 or 2 hours (cold insulin is more painful).

Preparation for administration

  • Wash hands.
  • Check the pen label (type and strength of insulin, expiry date) and inspect the solution (it should be clear, colourless and aqueous).
  • Stir the insulin by gently rolling the pen between the palms of the hands. Do not shake the pen.
  • Remove the cap from the pen.
  • Wipe the pen tip (rubber seal) with a disinfectant.
  • Attach a pen needle to the pen after removing the protective seal of the needle. Push the needle straight onto the pen and screw it on tightly.
  • Remove the outer cap of the needle and save it (you will need it to remove the needle after the injection).
  • Remove the inner cap of the needle.
  • Remove air from the pen. Pointing the needle upward, select one or two units on the pen, and gently tap the pen to move air bubbles to the top of the pen.
  • Press the injection button. A drop of insulin should appear on the tip of the needle. If no drop appears, change the needle and repeat this step.
  • Select the correct dose on the pen by turning the dose selector to the required number of units.

How to administer SC insulin

  • Insulin can be injected into the abdomen (two fingers away from the belly button), upper arm, buttocks, hips, buttocks, or the front or side of the thigh.
  • Repeatedly injecting insulin in the same area can cause lumps, swelling and thickened skin, which may interfere with proper absorption of the insulin. See the picture below on “rotating” injection sites.
  • Do not inject insulin into areas with wounds or bruising.
  • Clean the chosen injection site with soap and water. Allow to dry.
  • Pinch the skin.
  • Keep the pen straight at a 90-degree angle to the skin and insert the needle with one quick motion.
  • Push the injection button with the thumb to inject the dose of insulin. Wait for 10 seconds before releasing the button and removing the needle from the skin.
  • Apply gentle pressure on the injection site with a finger for 5-10 seconds to prevent insulin from leaking out.
  • Remove the needle from the pen by replacing the outer needle cap on and unscrewing. Leaving the needle on the pen can result in leakage or air bubbles.
  • Dispose of the needle safely in a sharps container.
  • After each injection, replace the cap on the pen to protect it from light.

Education of patients

Arrange multiple counselling sessions to assess whether the patient is ready to begin self-injecting and understands the risks and management of hypoglycaemia, the use of the pre-filled pen (including insulin units), the proper injection technique, insulin storage, and waste management. If possible, involve the family or caregivers and provide an information leaflet adapted to the local context. Contact your OC referent for more details.

Precautions for Use

Depending on the model, the number of units contained in a pen may vary. The pen is designed with a safety stop, so it is not possible to dial more units than what remains in the pen.

If the remaining units in the pen are insufficient for the full dose, inject the available amount with the current pen and use a new pen to administer the remaining dose (select.the missing amount).

Once the pen is empty, it should be discarded.

Remark:

The MSF NCD platform considers the following insulin aspart ultrarapid 100 UI/ml (3ml, pref. pens) products to be therapeutically equivalent: Novo Rapid FlexPen® (Nordisk) and Insulin Aspart ImpactFlexPen® (Sanofi). Patients receiving MSF care may be switched between the two products. Contact your NCD referent for more details when ordering.

Storage

  • Unopened pens: store in the refrigerator between 2ºC and 8ºC - Protect from sunlight
  • Pens in use : may be kept for up to 4 weeks at temperature not exceeding 30C.
  • Do not freeze. Discard any pen that has been frozen.
  • Do not store the pen with a needle attached.

(Cf Introduction: Thermosensitive products)